Congenica signs distribution agreement with AmpliTech in France
AmpliTech to distribute Congenica's world-leading NGS data analysis and clinical decision support software in France
Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces a new distribution agreement with AmpliTech, a leading French distribution company dedicated to the commercialisation of innovative products, software, and instruments for in vitro diagnostics and research.
AmpliTech distributes on behalf of major international providers of innovative diagnostic solutions in prenatal, postnatal, molecular genetics, as well as cancer diagnostics. The main customer targets are cytogenetics, molecular genetics and pathology labs in hospitals and research institutions in France, Belgium, Luxembourg and Switzerland.
As part of the agreement, AmpliTech will distribute Congenica’s clinical decision support software platform with a focus on rare diseases as Congenica’s product enters the French market.
Congenica’s technology platform is proven to enable rapid analysis and interpretation of complex genomic data, allowing the delivery of personalised medicine at scale.
The software enables rapid genomic data analysis at scale, performing 20x faster than industry averages and providing a 30% higher diagnostic yield, reducing genomic interpretation costs by up to 95%.
Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the UK National Health Service's Genomic Medicine Service.
Anna Tucker, Director of EMEA Distributor Sales, Congenica, said: “A key strategic priority for Congenica is to bring our class-leading genomic analysis platform to new markets, alongside expansion into further indications. By signing this distribution agreement, we are able to support the rapidly growing genomics market in France. AmpliTech has a strong reputation for its expertise in distribution and product development strategies and we look forward to working with them as our software is rolled out and increasingly integrated into routine clinical care.”
Gilles Cestelli, General Manager, AmpliTech, said:
AmpliTech’s focus is on delivering the innovative solutions of our partners and we believe that Congenica’s software has the potential to transform the genomic analysis capabilities of research institutions, diagnostic laboratories and hospitals throughout France. With the French genomics market growing rapidly we envisage a future where genomic medicine can be incorporated into standard clinical practice, enabled by Congenica.